Sebelius Kathleen

DirectorHumacyte, Inc. (HUMA) · full profile →Form 4 · filed Sep 11, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$28K
Net Open-Market Flow
-$28K
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 10, 2024Sell(S)2K$5.39$8K41K
Sep 10, 2024Option exercise(M)2K$3.35$8K43K
Sep 10, 2024Option exercise(M)5K$4.34$20K44K
Sep 10, 2024Sell(S)4K$5.41$20K40K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Sep 10, 2024Option exercise(M)5K$04K
Sep 10, 2024Option exercise(M)2K$06K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001818382-24-000186) within minutes of acceptance. Every field above traces to the original document. Verify it directly: